Diurnal Rhythm in Blood Pressure Is Preserved in Hypertensive Mice Despite Therapy With Mineralocorticoid Receptor Antagonists.

IF 2.2 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Diana S Usai, Olga Kudryavtseva, Morten B Thomsen
{"title":"Diurnal Rhythm in Blood Pressure Is Preserved in Hypertensive Mice Despite Therapy With Mineralocorticoid Receptor Antagonists.","authors":"Diana S Usai, Olga Kudryavtseva, Morten B Thomsen","doi":"10.1097/FJC.0000000000001812","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Human arterial blood pressure follows a circadian rhythm, where pressure is highest during the day and lowest during the night. Patients with hypertension can have either a preserved rhythm or a dampened rhythm with a lower day-to-night difference, called \"dippers\" and \"nondippers,\" respectively. Spironolactone, eplerenone, and the newer finerenone are mineralocorticoid receptor antagonists (MRAs) used for patients with resistant hypertension. In this study, we describe the 24h diurnal cycle in blood pressure in mice with and without hypertension to test whether high blood pressure induced a nondipping phenotype. Moreover, we tested whether the 3 MRAs affected the 24h cycles in blood pressure in the mice. Radiotelemetry devices were used to monitor blood pressure continuously in freely roaming mice (n = 19). Hypertension was induced by l -nitroarginine methyl ester ( l -NAME, 1 g/L) dissolved in the drinking water. A dipping phenotype was acknowledged if the nocturnal reduction in blood pressure was >10%. The 3 MRAs were administered orally once daily. Significant 24h rhythms were identified in blood pressure and 89% of the mice had a dipping phenotype at baseline. Only 42% of the hypertensive mice were dippers ( P > 0.05 vs. baseline). The MRAs at the doses tested did not change the 24h rhythm in blood pressure, and they did not restore a dipping phenotype in the nondipping hypertensive mice. Thus, l -NAME causes hypertension in mice and induces a \"nondipper\" phenotype in most of the mice. Spironolactone, eplerenone, or finerenone at the selected doses do not change arterial blood pressure in hypertensive mice.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"337-347"},"PeriodicalIF":2.2000,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FJC.0000000000001812","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Human arterial blood pressure follows a circadian rhythm, where pressure is highest during the day and lowest during the night. Patients with hypertension can have either a preserved rhythm or a dampened rhythm with a lower day-to-night difference, called "dippers" and "nondippers," respectively. Spironolactone, eplerenone, and the newer finerenone are mineralocorticoid receptor antagonists (MRAs) used for patients with resistant hypertension. In this study, we describe the 24h diurnal cycle in blood pressure in mice with and without hypertension to test whether high blood pressure induced a nondipping phenotype. Moreover, we tested whether the 3 MRAs affected the 24h cycles in blood pressure in the mice. Radiotelemetry devices were used to monitor blood pressure continuously in freely roaming mice (n = 19). Hypertension was induced by l -nitroarginine methyl ester ( l -NAME, 1 g/L) dissolved in the drinking water. A dipping phenotype was acknowledged if the nocturnal reduction in blood pressure was >10%. The 3 MRAs were administered orally once daily. Significant 24h rhythms were identified in blood pressure and 89% of the mice had a dipping phenotype at baseline. Only 42% of the hypertensive mice were dippers ( P > 0.05 vs. baseline). The MRAs at the doses tested did not change the 24h rhythm in blood pressure, and they did not restore a dipping phenotype in the nondipping hypertensive mice. Thus, l -NAME causes hypertension in mice and induces a "nondipper" phenotype in most of the mice. Spironolactone, eplerenone, or finerenone at the selected doses do not change arterial blood pressure in hypertensive mice.

尽管使用矿皮质激素受体拮抗剂治疗,高血压小鼠的血压昼夜节律仍保持不变。
人体动脉血压遵循昼夜节律,白天血压最高,晚上最低。高血压患者既可以有保持的节律,也可以有受抑制的节律,昼夜差异较小,分别称为“倾角”和“非倾角”。螺内酯、依普利酮和较新的芬尼酮是用于顽固性高血压患者的矿皮质激素受体拮抗剂(MRAs)。在本研究中,我们描述了高血压小鼠和非高血压小鼠的24小时昼夜血压周期,以测试高血压是否会诱导非浸入表型。此外,我们测试了三种mra是否影响小鼠的24小时血压周期。使用无线电遥测装置连续监测自由漫游小鼠的血压(n=19)。将1 g/L的L-硝基精氨酸甲酯(L- name, 1 g/L)溶解于饮用水中诱导高血压。如果夜间血压下降约为10%,则确认为下降表型。3种MRAs每日口服1次。在血压中发现了显著的24小时节律,89%的小鼠在基线时具有下降表型。只有42%的高血压小鼠是小叶鼠(与基线相比P < 0.05)。所测剂量的MRAs并没有改变血压的24小时节律,也没有恢复非浸入性高血压小鼠的浸入表型。因此,L-NAME在小鼠中引起高血压,并在大多数小鼠中诱导“非dip”表型。所选剂量的螺内酯、依普利酮或芬尼酮不会改变高血压小鼠的动脉血压。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.10
自引率
3.30%
发文量
367
审稿时长
1 months
期刊介绍: Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias. Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书